Long-term Extension of the Multinational, Double-blind, Placebo Controlled Study EFC6049 (HMR1726D/3001) to Document the Safety of Two Doses of Teriflunomide (7 and 14 mg) in Patients With Multiple Sclerosis With Relapses

Trial Profile

Long-term Extension of the Multinational, Double-blind, Placebo Controlled Study EFC6049 (HMR1726D/3001) to Document the Safety of Two Doses of Teriflunomide (7 and 14 mg) in Patients With Multiple Sclerosis With Relapses

Completed
Phase of Trial: Phase III

Latest Information Update: 28 Apr 2017

At a glance

  • Drugs Teriflunomide (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions; Registrational
  • Sponsors Sanofi
  • Most Recent Events

    • 28 Apr 2017 Results analysing the impact of long term treatment with Teriflunomide on disability outcomes from TEMSO and TOWER and their extension studies, presented at the 69th Annual Meeting of the American Academy of Neurology
    • 28 Apr 2017 Results investigating the association between brain volume loss (BVL) and long-term disability worsening (DW) in TEMSO and its extension presented at the 69th Annual Meeting of the American Academy of Neurology
    • 28 Apr 2017 Results of a pooled analysis in patients with progressive and relapsing MS from two randomized trials and their extensions (TEMSO and TOWER; n=122), presented at the 69th Annual Meeting of the American Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top